Neuropathy — Nerve Damage and Cancer Treatments

Neuropathy denotes a pathological disturbance or functional impairment within peripheral nerves. These nerves form an intricate communication network transmitting sensory data, motor instructions, and autonomic signals between the central nervous system and the remainder of the body. Damage may involve the protective myelin sheath, the underlying axon, or both, disrupting neural transmission.

Chemotherapy-induced peripheral neuropathy (CIPN) is the most frequent presentation in oncology. Antineoplastic agents can accumulate in dorsal root ganglia or disrupt axonal transport mechanisms, leading to symmetrical sensory changes that classically follow a 'glove-and-stocking' distribution. In some individuals, neuropathy can also affect motor pathways, leading to muscle weakness, or the autonomic nervous system, causing blood pressure dysregulation and gastrointestinal transit disturbances.

Neuropathy directly affects a person's comfort, balance, and independence. Because persistent or worsening nerve injury can sometimes become permanent, clinical teams take early symptoms seriously. Reporting changes in sensation allows doctors to alter medication doses, lengthen time between cycles, or switch therapies before nerve damage deepens. Managing neuropathy effectively prevents accidental falls, sustains fine motor coordination, and ensures cancer therapy remains tolerable throughout the full course.

Neuropathy is diagnosed primarily through careful clinical assessment. Clinicians evaluate tendon reflexes, vibration detection using a tuning fork, temperature sensitivity, and response to light touch with a monofilament. Validated patient-reported symptom questionnaires are widely used. Specialized neurophysiological tests, such as nerve conduction studies or electromyography, are reserved for complex or atypical cases.

Neuropathy is commonly observed in individuals receiving neurotoxic chemotherapy for breast, colorectal, ovarian, lung, and prostate cancers. It also affects patients with haematological conditions such as multiple myeloma and non-Hodgkin lymphoma, where both the disease itself and therapies like proteasome inhibitors or immunomodulatory drugs influence peripheral nerve health.

Drugs with high neurotoxic potential include taxanes (paclitaxel, docetaxel), platinum compounds (oxaliplatin, cisplatin), vinca alkaloids (vincristine), and proteasome inhibitors (bortezomib). Management centres on dose reductions, treatment pauses, or regimen modifications. For symptom control, doctors may prescribe nerve pain medications such as duloxetine, gabapentin, or pregabalin, alongside physical therapy and occupational balance support.